The antiviral activity of a series of benzimidazole derivatives and substituted benzimidazole β-Land β-D-2'-deoxyribonucleosides against selected RNA and DNA viruses including HIV-1, BVDV, YFV, DENV-2, WNV, HBV, HCV and human RSV was evaluated. In addition, the synthesis of several benzimidazole β-L-2'-deoxyribonucleosides (1-4) and 2'-deoxy-2'-fluoro-β-D-arabinofuranosyl nucleoside 5 is described. The stereoselective glycosylation of the anions of the functionalized benzimidazoles 6a, 12a and 28 with 3,5-di-O-(4-methylbenzoyl)-2-deoxy-α-L-erythro-pentofuranosyl chloride (29) furnished β-L-2'-deoxyribonucleosides 1-4 while the glycosylation of the anion of 2-bromobenzimidazole (12a) with 3,5-di-O-benzoyl-2-deoxy-2-fluoro-α-D-arabinofuranosyl bromide 34 gave the 2'-deoxy-2-fluoro-β-D-arabinofuranosyl nucleoside 5. Moreover, the crystal structure of the benzoylated 2-bromobenzimidazole 2'-deoxy-2'-fluoro-β-D-arabinofuranosyl nucleoside 35 is reported.
Introduction
The benzimidazole system is an integral part of numerous antiparasitic, fungicidal, anthelmintic and anti-inflammatory drugs.
1, 2 Among them, modified 2-trifluoromethyl-benzimidazoles are particular promising as they show appreciable herbicidal activity due to the inhibition of photosynthesis. 3 Recently, potent anticancer, antibacterial, antifungal and antiprotozoal activities were reported for halogenated 2-trifluoromethyl-and 2-pentafluoroethyl-benzimidazoles. [4] [5] [6] Not only the substituted benzimidazole heterocycles themselves but also a series of modified benzimidazole nucleosides are biologically active. [7] [8] [9] Originally, their synthesis was encouraged by the discovery that 5,6-dimethyl-1-(α-D-erythro-pentofuranosyl)-benzimidazole is a constituent of vitamin B12. 10 5,6-Dichlorobenzimidazole ribonucleoside (DRB) inhibits cellular and viral RNA synthesis. 11, 12 However, this activity is accompanied by a substantial cytotoxicity and therefore this compound has not found application as an antiviral drug. 13, 14 Noteworthy is the recent finding that the L-ribonucleoside of 5,6-dichloro-2-isopropylaminobenzimidazole (1263W94) shows increased activity against the herpes virus HCMV (human cytomegalovirus) in vitro compared to its parent compound 2-bromo-5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (BDCRB) and a low cytotoxicity. 15 This is in line with the general observation that several L-nucleosides exhibit an antiviral activity comparable and sometimes greater than their D-enantiomers, due to a more favourable toxicological profile and a greater metabolic stability. 16, 17 Thus, various L-nucleosides have been synthesized as potential antiviral and anticancer drugs such as 3TC (lamivudine), FTC (emtricitabine) and L-FMAU (clevudine). [16] [17] [18] [19] [20] The first synthesis of a L-nucleoside (β-L-dT) was reported in 1964 by Šmekal and Šorm 21 followed by the description of β-L-adenosine by Acton, Ryan and Goodman in the same year. 22 Furthermore, the anti-hepatitis B virus activity of the 2'-deoxyribonucleoside L-dT (Telbivudine, Tyzeka TM , Sebivo TM ) 21b against hepatitis B virus infection led to its approval as antiviral drug.
Herein, we report on the antiviral activity of benzimidazole derivatives against Flaviviridae, human immunodeficiency retrovirus (HIV- Some of them were already described by Baczynski and Niementowski in 1902 and Büchel in 1970, respectively, 23, 24 others were recently reported. 5, 6, 25, 26 The introduction of side chains into position-2 of halogenated or non-halogenated benzimidazoles can be achieved by different routes. 5, 6, [25] [26] [27] One route uses non-halogenated or halogenated o-phenylenediamines as precursor which give after condensation with carboxylic acids and their derivatives (nitriles, imidates, orthoesters) the 2-substituted benzimidazoles (Scheme 1). In this manuscript compounds of Figure 4 were prepared employing this protocol. 5, 6 In another route 2,4,5,6,7-pentabrominated benzimidazole is subjected to a series of displacement reactions in position-2 using various nucleophiles (Scheme 2). 25 Compounds shown in Figure 3 were synthesized according to this route. 
Results and Discussion
Antiviral activity and cytotoxicity A series of benzimidazole derivatives and benzimidazole β-L-and β-D-2'-deoxyribonucleosides were evaluated in cell-based assays by determining the 50% cytotoxicity concentration (CC50) and the 50% inhibitory concentration (EC50) as previously described. 28 Among the tested viruses, representatives of three genera of the Flaviviridae which belong to the class of positive-sense single-stranded RNA (ssRNA + ) viruses were selected. These are Pestivirus (bovine viral diarrhoea virus, BVDV), Flavivirus including yellow fever virus (YFV), dengue virus type 2 (DENV-2) and West Nile virus (WNV) and Hepacivirus (hepatitis C virus; HCV). Moreover, activity against the representative member of the Retroviridae (ssRNA + ) the human immunodeficiency retrovirus (HIV-1) and the DNA virus Hepatitis B (HBV) was evaluated as well as the activity against the negative-sense single-stranded RNA virus (ssRNA -) Human Respiratory Syncytial Virus (human RSV). The data are summarized in Tables 1-7 7c ≥100 >100 >100 >100 >100 >100 >100 >100 >100 >100 7d >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 7j ≥100 >100 >100 >100 >100 >100 >100 >100 >100 >100 7k 68 >68 >100 >100 >100 >100 >100 >100 >100 >100 7v 76 >76 >100 >100 >100 >100 >100 >100 >100 >100 7w >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 8d 80 >80 >100 >100 >100 >100 >100 >100 >100 >100 9n ≥100 >100 >100 >100 >100 >100 >100 >100 >100 >100 10 ≥100 >100 77 >77 >100 >100 >100 >100 >100 >100 11 ≥100 >100 >100 >100 >100 >100 >100 >100 >100 >100 In the series of 4,5,6,7-tetrabrominated benzimidazole derivatives ( Figure 3 ) no compound showing a significant selective activity against one of the ssRNA + viruses HIV-1, BVDV, YFV, DENV-2 or WNV could be identified as shown in Table 1 . Among them, compounds 6h, 6l and 6p exhibit a certain antiviral activity against HIV-1, YFV, DENV-2 or WNV. However, the antiviral activity is accompanied by cytotoxicity for the host cell lines within the same concentration range.
The closely related 4,5,6,7-tetrabromobenzimidazole derivatives 6d-g having a trifluoromethyl, pentafluoroethyl, heptafluoropropyl or nonafluorobutyl side chain attached to position-2 of the benzimidazole ring exhibit strong cytotoxicity against the host cell lines in the low micromolar range (0.5-2.0 µM). On the other hand compounds 7d and 7w are completely inactive against all the tested ssRNA + viruses and are also not cytotoxic. 12a >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 12c >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 12d >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 12e 44 >44 >100 >100 >100 >100 >100 >100 >100 >100 12q >100 64 >100 >100 >100 >100 >100 >100 >100 >100 17g >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 17k >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 17l >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 Table 1 .
Next, various non-halogenated, chlorinated and brominated benzimidazole derivatives as well as 2-carboxybenzimidazoles ( Figure 4) were evaluated for their antiviral activity against ssRNA + viruses (HIV-1, BVDV, YFV, DENV-2, WNV). Unfortunately, the compounds of this series do not show selective antiviral activity against any of the tested ssRNA + viruses. The moderate antiviral activities of 13g, 14f, 16f, 16g, 16m and 16o are accompanied by cytotoxicity against the host cell lines within the same concentration range as it was also observed for the 4,5,6,7-tetra-brominated benzimidazoles shown above.
However, from the data given in Table 2 it can be seen that compounds 14d, 16c, 18, 19 and 21-23 are strongly cytotoxic within a range of 1.0-4.0 µM in all tested cell lines whereas compounds 12a, 12c, 12d, 13f, 17g, 17k and 17l are completely inactive against all tested ssRNA + viruses and are also non-cytotoxic. 25a >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 25b >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 25c >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 25d >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 25e >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 25f >100 >100 >100 >100 >100 >100 >100 >100 >100 >100
a Retroviridae. b Pestivirus. c Flavivirus. j For details of the antiviral assays see Table 1 .
The data summarized in Table 3 show that none of the nitrobenzimidazole derivatives ( Figure 5 ) exhibit selective antiviral activity against ssRNA + viruses. Compound 24g is cytotoxic against the cell line used in the HIV-1 assay while compound 24h is toxic against all tested cell lines.
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3 >100 >100 >100 >100 >100 >100 >100 >100 n.d. >100 4 7.9 >7.9 5 >5 5 >5 6.5 >6.5 6.5 >6.5 5 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 26a >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 Then, the benzimidazole β-L-2'-deoxyribonucleosides 1-4 as well as the fluoroarabino nucleoside 5 ( Figure 2 ) and closely related β-D-2'-deoxyribonucleosides (26a, 27; Figure 6 ) were screened for their antiviral activity against ssRNA + viruses as demonstrated by Table 4 . 29 Among them, the 4,5,6,7-tetrabrominated benzimidazole β-L-2'-deoxyribonucleoside 4 as well as its corresponding β-D-enantiomer 27 show similar antiviral activity against the tested ssRNA + viruses. However, these compounds are also cytotoxic against the host cell lines within the same concentration range. For comparison, 4,5,6,7-tetrabromobenzimidazole 6a also exhibits antiviral activity accompanied by toxicity (see Table 1 ). The 4,5,6,7-tetrabrominated benzimidazole 2'-deoxyribonucleosides 4 and 27 are more toxic than the heterocycle 6a itself. It can be assumed that the nucleosides can enter the cells more efficiently and function as a release system delivering the active benzimidazole derivative 6a. Unfortunately, the other benzimidazole L-and D-nucleosides show no antiviral activity and are non-toxic.
Page 236  ARKAT USA, Inc. Several benzimidazole derivatives were also tested for their activity against the Hepatitis B virus (HBV) which belongs to the DNA viruses. In this assay the 50% inhibitory concentration (EC50) was determined for the virion (Vir) and the replicative intermediate (RI) of HBV. Table 5 shows that within the tested compounds the 4,5,6,7-tetrabrominated benzimidazole derivatives 6j and 7j both carrying a dimethylamino side chain attached to position-2 of the heterocycle show anti-HBV activity against the virion and the replicative intermediate in a low micromolar concentration range (6j: EC50 (RI) = 5.0 µM, EC50 (Vir) = 1.0 µM and 7j: EC50 (RI) = 0.8 µM, EC50 (Vir) = 0.6 µM) while the cytotoxicity is less pronounced (6j: CC50 = 100 µM and 7j: CC50 >100 µM). Interestingly, among the 4,5,6,7-tetrabrominated benzimidazoles having different side chains attached to position-2 ( Figure 3) several compounds (6a, h, i, k, o) are toxic in low concentration (<1 µM). Apart from the L-nucleoside 4 which is cytotoxic the tested nucleosides 1-3, 5 are without activity.
Page 238  ARKAT USA, Inc. Regarding the activity in the HCV replicon system a series of benzimidazoles were selected for testing (Table 6 ). Their ability to inhibit the HCV replicon replication at the test concentration of 15µM was evaluated by an HCV replicon assay (ELISA) as previously described. 28 The cellular toxicity was determined at the test concentration of 15µM of drug. 28 For most compounds inhibition of the HCV replicon replication is accompanied by cytotoxicity. Only in case of 6c, 7w and 12e inhibition was observed without cytotoxicity.
Page 239  ARKAT USA, Inc. The Respiratory Syncytial Virus (RSV) is a major cause of respiratory illness in infants and young children. However, antiviral approaches are still required to treat this infection. From Table 7 it can be seen that none of the tested benzimidazole derivatives show selective antiviral activity against RSV. The compounds are either toxic or completely inactive. However, in the series of the halogenated benzimidazoles including the 4,5,6,7-tetrabrominated benzimidazole Lnucleoside 4 most compounds are cytotoxic. Spectroscopic data and single crystal X-ray analysis. Compounds 1-5 as well as their intermediates were characterized by 1 H NMR spectra (experimental section) and 13 C-NMR spectra (Table 8) as well as by elemental analysis. For the benzimidazole β-L-2'-deoxyribonucleosides 1-2 and 30-31 the assignment of the 13 C-NMR chemical shifts were made according to the corresponding D-nucleosides. 36 For compounds 4, 33 the 13 C-NMR signals of the functionalized benzimidazole nucleobases were assigned according to 13 C-NMR chemical shifts of the non-brominated benzimidazole nucleoside (26b) (Figure 6 ). 37 Moreover, gated decoupled 1 H-13 C NMR spectra were measured to confirm the assignment of the 13 C-signals of nucleosides 5, 32 and 35 (Table 9 ). For the 2-bromobenzimidazole 2'-deoxy-2'-fluoro-β-D-arabinofuranosyl nucleosides 35 and 5 the presence of the fluorine atome in the sugar moiety was confirmed by 19 F-NMR spectra (35: -194.2 ppm and 5: -194.0 ppm). Moreover, JC,F coupling constants are given in Table 9 . Table 8 . Furthermore, the solid state structure of the benzoylated 2-bromo-1-[2-deoxy-2-fluoro-β-Darabinofuranosyl]-benzimidazole 35 was confirmed by single-crystal x-ray analysis. 38 From the crystal structure of 35, the orientation of the nucleobase relative to the sugar moiety was determined to be syn with χ = (O1'-C1'-N11-C18) = 39.7 (9) o . The natural 2'-deoxyribonucleosides usually adopt an anti conformation. However, it is observed that the introduction of a bulky substituent in position-2 of the heterocyclic moiety shifts the conformation around the glycosylic bond from anti to syn as it was recently reported for 2'-deoxyimmunosine. 39 The sugar moiety of 35 shows a pseudorotation phase angle P of 118.8° and a maximum amplitude of puckering τm of 41.8° which indicates a south (S) conformation. This result is in contrast to many other 2'-fluoroarabino nucleosides that are in N-conformation. However, the conformation of the sugar residue is also strongly influenced by the benzoyl protecting groups. 
Nucleoside Synthesis Synthesis of benzimidazole β-L-2'-deoxyribonucleosides

C NMR chemical shifts of benzimidazole β-L-and β-D-2'-deoxyribonucleosides
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Conclusions
The antiviral activity of a series of benzimidazole derivatives and substituted benzimidazole β-L-and β-D-nucleosides against selected RNA and DNA viruses including HIV-1, BVDV, YFV, DENV-2, WNV, HBV, HCV and human RSV was evaluated. Unfortunately, no selective antiviral activity was observed for the tested compounds. However, among the halogenated benzimidazoles including the 4,5,6,7-tetrabrominated benzimidazoles β-L-2'-deoxyribonucleoside 4 several derivatives were found to be cytotoxic against the tested cell lines. 1-[2-Deoxy-3,5-di-O-(4-methylbenzoyl)-β-L-erythro-pentofuranosyl]-4,5,6 ,7-tetrabromobenzimidazole (33). NaH (80 mg, 2 mmol, 60% in oil) was added portionwise to a suspension of 4,5,6,7-tetrabromobenzimidazole (6a; 651 mg, 1.5 mmol) in anhyd. MeCN (25 ml) at room temperature. The reaction mixture was stirred for additional 10 min at rt and then heated under reflux for 10 min. Compound 29 (583.5 mg, 1.5 mmol) was added, and stirring was continued for 20 min at rt. The reaction mixture was diluted with CH2Cl2 (20 ml), filtered through a Celite pad, and the filtrate was evaporated. The dry material was applied onto FC (silica gel, column 3. 
